Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL644521 | 0.83 | LMNA (0.46) | LMNAMAPK1TRPA1CYP2D6RIPK1 | |
| SCHEMBL644520 | 0.83 | LMNA (0.46) | LMNAMAPK1TRPA1CYP2D6RIPK1 | |
| SCHEMBL13739244 | 0.83 | LMNA (0.46) | LMNAMAPK1TRPA1CYP2D6RIPK1 | |
| Trifluoroacetic Acid SCHEMBL31316324 | 0.79 | LMNA (0.39) | LMNAADRB2ADRB1ADRB3TSHR | |
| SCHEMBL16248050 | 0.77 | LMNA (0.50) | LMNAMAPK1TRPA1CYP2D6ADRB2 | |
| SCHEMBL703501 | 0.76 | LTA4H (0.32) | MAPK1RIPK1KDM4EALDH1A1 | |
| SCHEMBL19440164 | 0.74 | LMNA (0.47) | LMNAMAPK1CYP2D6ADRB2ADRB1 | |
| SCHEMBL707647 | 0.73 | LMNA (0.35) | LMNAMAPK1KDM4EALDH1A1 | |
| SCHEMBL714783 | 0.72 | RIPK1 (0.34) | MAPK1RIPK1ALDH1A1 | |
| SCHEMBL24312400 | 0.70 | CYP2D6 (0.38) | LMNACYP2D6ADRB2ADRB1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673942-B2 | Fused ring compounds and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-18 | — | — | US | disclosed |
| US-20110098297-A1 | FUSED RING COMPOUNDS AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-04-28 | — | — | US | disclosed |
| EP-2276760-A1 | FUSED RING COMPOUNDS AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009125873-A1 | FUSED RING COMPOUNDS AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098297-A1 | FUSED RING COMPOUNDS AND USE THEREOF | GCKR, GPR119, SLC5A1 | LMNA 4368/4885MAPK1 517/4885TRPA1 2659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.